Royal Bank Of Canada reiterated their sector perform rating on shares of Severn Trent (LON:SVT – Free Report) in a report released on Monday, Marketbeat.com reports. The brokerage currently has a GBX 2,850 price objective on the stock.
Several other research firms have also recently issued reports on SVT. Jefferies Financial Group reaffirmed a “hold” rating and issued a GBX 2,610 price objective on shares of Severn Trent in a research report on Wednesday, October 1st. Barclays upped their price objective on Severn Trent from GBX 2,960 to GBX 3,385 and gave the company an “equal weight” rating in a research report on Wednesday, August 20th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Severn Trent currently has an average rating of “Hold” and an average price target of GBX 2,861.25.
Check Out Our Latest Research Report on SVT
Severn Trent Stock Performance
Insider Buying and Selling at Severn Trent
In other Severn Trent news, insider Olivia (Liv) Garfield sold 28,287 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of GBX 2,673, for a total value of £756,111.51. Also, insider Helen Miles sold 8,067 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of GBX 2,673, for a total value of £215,630.91. Corporate insiders own 0.29% of the company’s stock.
Severn Trent Company Profile
As one of Britain’s largest water companies, we supply fresh, clean drinking water to over nine million people across our region – around two billion litres every day. Once used, we collect, clean, and treat the water before safely returning it to the environment. We are one of only three listed water stocks in the UK, offering a valuable combination of reliable earnings, long-term asset growth, and inflation-linked dividends.
Read More
- Five stocks we like better than Severn Trent
- How to Short a Stock in 5 Easy Steps
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How to Invest in Blue Chip Stocks
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- How to Short Nasdaq: An Easy-to-Follow Guide
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Severn Trent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Severn Trent and related companies with MarketBeat.com's FREE daily email newsletter.